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Abstract 
Canada continues to struggle with high rates of unplanned pregnancies resulting in 
significant health, financial, and social implications. The best strategy in preventing unplanned 
pregnancies is with regular use of reliable and safe contraception. In Canada, most women rely 
on oral hormones and male condoms as their primary means of contraception, despite their 
reduced efficacy. IUDs, on the other hand, are a highly reliable, safe and reversible form of 
contraception, yet many Canadian women do not use them.  
A thorough literature review found that many factors act as barriers to IUD use in 
Canada, which were found to be impeding IUD use in Canada. Three categories of barriers to 
IUD use were identified: those associated with the IUD user, those associated with the healthcare 
provider, and those associated with the healthcare system. In response to these barriers, I have 
targeted a collection of strategies that could be implemented to help reduce them to assure 
reliable accessibility to IUDs in Canada.  
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Chapter 1: Introduction and Background 
Canada is a nation with disproportionately high rates of unplanned pregnancies, most 
arising from ineffective contraception or contraception failure (Black et al., 2015). Unplanned 
pregnancies are especially prominent among vulnerable women including youth, First Nations, 
immigrant and poor populations (Aptekman, Rashid, Wright & Dunn, 2014; Weibe, 2013; Black 
et al., 2015). This disproportionate representation of unplanned pregnancies among vulnerable 
Canadians is a financial, healthcare, and social justice issue. With an annual estimate of 180,000 
unplanned pregnancies, Canada spends an additional 140 million dollars on deliveries and 
abortions (Black et al., 2015). Moreover, health complications for the fetus and the mother are 
more likely with unintended pregnancies. As a society that prides itself on public, 
comprehensive, universal, portable and accessible healthcare (Canada Health Act, 1984), reliable 
contraception must remain available to all women. To rectify this financial, health, and social 
justice issue, Canada could benefit from increased rates of reliable contraception such as 
Intrauterine Devices (IUDs). IUDs are readily used in many other countries, however, in Canada 
they make up less than 1% of all contraception methods. This literature review looks at the 
barriers Canadian women face obtaining IUDs and subsequently makes recommendations for 
strategies to remove these barriers.  
The Importance of Contraception 
The International Survey of Married and Unmarried women found that 57% of all fertile 
women want to avoid pregnancy (Darroch & Singh, 2013). Despite this, only half of these 
women use reliable modern contraception (United Nations, 2011). The remaining 44% either 
depend on unreliable methods or they use none, making them a very high risk for unplanned 
pregnancies. This discrepancy between the desire to avoid pregnancy and taking appropriate 
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action to do so is a gap between knowledge, attitudes, and practices (KAP). This concept was 
initially explored in the 70's by Bogue (1974), coining it as the KAP-gap. Bogue (1974) found 
five key reasons that women may not take appropriate action to prevent pregnancies: undesired 
side effects of contraction, a fear of modern contraception, misinformation about contraception 
from providers, mistrust towards the healthcare system, and disappointments from previous 
contraception experiences. Other important factors that contribute to the KAP-gap include 
institutional and systemic barriers such as a lack of accessibility and availability.  
The World Health Organization (WHO) describes contraception as a basic human right 
by which a woman can control her fertility (Cottingham & Ravindram, 2015). WHO has outlined 
nine parameters necessary for providing this human right. Contraception must be 
• provided without discrimination,  
• available in sufficient quantity,  
• accessible both physically and economically,  
• provided with acceptable information and services, 
• high quality (including the contraception, the counseling, and the services), 
• included with information for decision making,  
• provided with privacy and confidentiality, 
• in participation with the woman selecting it. 
Nations should be held accountable for upholding the above principles. By meeting these nine 
parameters, we should be able to reach a state where all women who want to avoid pregnancy 
can. Until we achieve this, the KAP-gap will persist, and many women will remain at risk of 
unplanned pregnancies. 
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Unplanned Pregnancies  
Unplanned pregnancies are difficult to quantify. The variables can be difficult to define, 
and the methods of measurement are often biased. Gipson, Koenig, and Hindin (2008) discussed 
this challenge in their systematic review, which sought to quantify the effects of unplanned 
pregnancies. They found that the definition of unplanned pregnancies varies among studies; 
some classified a pregnancy into a dichotomy of wanted or unwanted, while others included a 
third term: mistimed. Gipson et al. (2008) also found many biases associated with the data 
collection process. They found pregnancy intentionality could change as time elapsed, and if the 
circumstances for raising a child changed. Gipson et al. (2008) also found that many of these 
studies rely on cross-sectional, retrospective reports, which were fraught with recall bias. 
Objective measurements, such as abortion rates, can be used to estimate the rate of 
unplanned pregnancies. Finer and Henshaw (2006) found that only 5% of all medically 
terminated pregnancies are intended at conception, so this could be used as an indicator for 
unintended pregnancies. In Canada, more than 81 000 abortions were performed in 2014, and 
100 000 in 2015 (Canadian Institute for Health Information (CIHI), 2016). Since 95% of medical 
abortions occur from unplanned pregnancies (Finer & Henshaw, 2006), this surge in abortions 
suggests that unplanned pregnancies may also be on the rise. Abortion rates alone, however, 
underestimate unplanned pregnancies, as many women may choose not to terminate them.  
Even though there is no reliable or consistent method to measure unplanned pregnancies, 
many experts have collaborated to make these estimations. Using birth data, abortion rates, 
surveys, and expert opinions, Black et al. (2015) estimated that up to 40% of all pregnancies in 
Canada are unplanned. This Canadian approximation is similar to a North American estimate of 
48% (Singh, Sedgh, & Hussain, 2010), and an American estimate of 45% (Finer & Zolna, 2016). 
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Regardless of how we assess the intentionality of pregnancies in Canada, almost half are 
unplanned. This remains an issue that must be addressed as it has considerable effects on 
mothers, their families, and society.  
The Impact of Unplanned Pregnancies 
Unplanned pregnancies are commonplace in Canada (Black et al., 2015). They can affect 
the health of the unborn fetus and the mother, impose a social and personal economic burden, 
and affect the quality of life of women and their families.  
Health of the fetus and mother. Unplanned pregnancies have health implications for 
both the fetus and the mother. Mohllajee, Curtis, Morrow, and Marchbanks (2007) found that 
pregnancy intention was an indicator for poor fetal outcomes including preterm delivery and low 
birth weight. It's hard to speculate whether an unplanned pregnancy is a risk factor for these 
outcomes, or whether it is an indicator for other factors such a late prenatal care or prenatal 
exposure to teratogens. In either case, improved fetal health is associated with planned versus 
unplanned pregnancies (Mohllajee et al., 2007).  
The maternal health effects of an unplanned pregnancy include higher rates of premature 
rupture of membranes, pregnancy induced hypertension, and depression (Mohllajee, et al., 2007). 
Furthermore, mothers of unplanned pregnancies are also more likely to engage in harmful health 
practices such as smoking, high caffeine intake, less exercise, poorer diet, and lower rates of 
vitamin supplementation (Yanikkerem, Ay, & Piro, 2013). Additionally, the fetus is at higher 
risk of inadvertent exposure to teratogenic medications and alcohol (Yanikkerem, Ay, & Piro, 
2013). By preventing unplanned pregnancies, we can improve the health and well-being of 
mothers and their prospective children.  
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Economic implications for unplanned pregnancies. In an experimental cost model, 
Black et al. (2015) estimated that each unintended pregnancy in Canada costs an average of 
$2100. This estimate accounts for the cost of common fetal outcomes: birth, induced abortion, 
miscarriage or ectopic pregnancy (Black et al., 2015). Since most births in Canada are publically 
financed, this equates to an annual public cost is $320 million (Black et al., 2015). This, 
however, underestimates the total cost, as it only includes the direct medical costs associated 
with these four fetal outcomes. Other expenses include the social costs of unplanned pregnancies 
such as adoption, fostering, childcare; and the personal costs incurred from lost wages and 
having an additional child (Udeh, Losech, & Spies, 2009). Though the estimated by Black et al. 
(2015) provide what is likely a significant underestimation, their conclusion remains: by 
improving reliable contraceptive methods in Canada, we can prevent unplanned pregnancies, and 
reduce this economic burden.  
Quality of life. Schwarz, Smith, Steinauer, Reeves, and Caughey (2008) assessed the 
effect that an unplanned pregnancy has on women's quality of life. They found that each case can 
have severe implications, affecting her education, work, family and social life. Limiting 
pregnancies to those that are planned, can help to reduce these negative impacts on quality of 
life.   
A large Canadian survey found that 35% of women meet the criteria for having an unmet 
need for contraception (Black et al., 2009). This unmet need directly affects the rate of 
unplanned pregnancies. Unplanned pregnancies are expensive, they influence the health of our 
women and their children, and they impact the quality of their life. Canada needs to improve its 
contraception use, but what are our options?  
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Contraception Methods 
There are many methods of contraception approved for use in Canada. Each can be 
classified based on their mechanism of action and their duration of effect. These include barrier 
methods, short-acting, long-acting reversible, long-acting non-reversible, and other methods.  
The efficacy of contraception types is often reported as perfect-use, or typical-use failure rates 
(Zildar, Upadhyay, & Lande, 2011). These rates are reported as the number of women out of a 
hundred who become pregnant during the first 12 months of use. Perfect-use failure rates are 
often measured during clinical trials when a woman and her partner follow the exact directions 
for use, yet they still become pregnant. It represents the efficacy of the contraception in a 
controlled setting, and with perfect use. Typical-use failure rates, on the other hand, measure the 
real-world effectiveness of the contraception using population-based survey data. The typical-use 
failure rate is a realistic measurement of a methods efficacy taking into consideration user 
compliance, human error, and other real-life variables. Typical-use failure is measured on an 
ongoing basis after the contraception has been used for many years which means efficacy can 
vary depending on the source of the data. A recent large-scale American review of contraception 
effectiveness was published by Sundaram et al. (2017). This recent publication is in use for the 
remainder of this discussion. 
Barrier methods. Barrier methods include the male condoms, female condoms, the 
diaphragm, and others. These methods all operate on the same principle: by providing a physical 
or chemical barrier to the sperm, preventing its passage through the cervical canal. The most 
common barrier method is the male condom, accounting for 15% of contraception use in Canada, 
while female barrier methods are less common: the female condom, diaphragm, cervical cap, and 
spermicides together account for less than 1% of all contraception use in Canada (United 
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Nations, 2011). Barrier methods are highly available in Canada as they do not require a 
prescription and are cheap to obtain; furthermore, some have the added benefit of preventing STI 
transmission. The disadvantage of these methods, however, is that they need to be applied with 
each sexual encounter, making them highly susceptible to typical-use failure. Male condoms, for 
example, have a 2% perfect-use failure rate (Zildar et al., 2011); however, in the real-world, 
typical-use failure rises to 12.6% (Sundaram et al., 2017). Female condoms have a typical-use 
failure rate of 21%, a factor that has been attributed, in part, to poor compliance (Zildar et al., 
2011). The availability and simplicity of male and female condoms make them invaluable in 
preventing unplanned pregnancies and reducing the spread of STIs, however, due to their high 
typical-use failure rates they should not be relied on as the sole contraceptive method for 
pregnancy prevention.  
Oral contraception. Oral contraception (The Pill) is a daily low-dose of estrogen, 
progesterone, or both, that is taken orally. Depending on the hormone used, the pill prevents 
ovulation, implantation, or endometrial proliferation. The Pill is one of the most widely used 
methods of contraception in Canada accounting for 21% of contraception, though it only 
accounts for 8% of contraception worldwide (United Nations, 2011). The efficacy of The Pill 
depends on how regular it is used, how often it is missed in a cycle, and the variability of when it 
is taken each day. For example, the perfect-use failure rate of The Pill is 0.3% (Zildar et al., 
2011), but this increases to 7.2% with typical-use (Sundaram et al., 2017). Oral contraception is 
effective, and widely used in Canada, but its typical-use failure rates make it less reliable. It is, 
therefore, a poor option for those who are unable to take a daily pill reliably. 
Injectable progesterone. Progesterone can be injected intramuscularly every 2-3 months. This 
synthetic progesterone is absorbed slowly over several months and interrupts the hormones in the 
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hypothalamic-pituitary-gonadal axis preventing ovulation, reducing fertility. It accounts for 3.5% 
of the worlds contraception use, and 1% of contraception in Canada (United Nations, 2011). The 
advantage is that it is only required every few months and it does not contain estrogen, making it 
an option for women who are estrogen intolerant or for whom estrogen is contraindicated. If 
taken regularly, injectable progesterone is highly effective, though it requires regularly scheduled 
injections to maintain its efficacy. This result is that the perfect-use failure rate of 0.3% to 
increase to 4% with typical use (Sundaram et al., 2017).  
Permanent contraception. Permanent contraception is a non-reversible method that 
involves a surgical procedure to induce sterilization. While these methods are highly effective, 
they are non-reversible and should, therefore, be reserved for families who have completed 
reproduction.  
Female sterilization otherwise known as tubal ligation or tying the tubes is a procedure 
that either cuts or blocks both fallopian tubes, preventing the ovum from meeting the sperm. It 
provides effective, life-long contraception; and notwithstanding the low-risk surgical procedure, 
it has very few side effects (Zildar et al., 2011). Three methods are used: hysteroscopy 
sterilization, laparoscopic band application and laparoscopic coagulation, each varies slightly in 
efficacy (Gariepy, Creinin, Smith, & Xu, 2014). Together they account for 11% of contraception 
used in Canada, and 19% worldwide (United Nations, 2011). The failure rate of female 
sterilization varies depending on the method used, and there are rare cases of previously effective 
tubal ligations independently reversing themselves (Patil & Jensen, 2016), as such, the failure 
rate is approximately 0.5% (Zildar et al., 2011). In some instances, salpingectomies, 
oophorectomies, and hysterectomies have failure rates that approach zero percent. In these cases, 
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however, contraception has been achieved secondarily through a procedure performed for a 
purpose other than contraception.    
Male sterilization, known as a vasectomy, is a simple surgical procedure that cuts or 
blocks the vas deferens, preventing sperm from entering the semen (Zildar et al., 2011). In 
Canada, 22% of contraception users rely on male sterilization (United Nations, 2011). Unlike a 
tubal ligation, the efficacy of a vasectomy can be confirmed through a semen analysis. Initially, 
the failure rate of a vasectomy is 2-3%, but this decreases with each year that passes. A 
vasectomy can be reversed; however, it is expensive, and often ineffective (Zildar et al., 2011). 
Traditional methods. There is a set of contraception techniques collectively referred to 
as traditional methods that involve modifying the method or timing of intercourse to prevent 
pregnancy. Fertility awareness methods, also known as timing or natural family planning, require 
a woman to know when she is fertile and to avoid intercourse during that time. Several strategies 
that can be used to track the ovarian cycle such as following the date on a calendar, monitoring 
symptoms such as cervical secretions, and basal body temperature. Other methods include 
withdrawal, whereby the man removes his penis from the vagina during intercourse before 
ejaculation (Zildar et al., 2011). These traditional methods account for 6% of the global 
contraception method, and up to 9% of the contraception in Canada (United Nations, 2011). 
Pregnancy rates for traditional methods range from 22-26% (Polis et al., 2016) making them the 
most unreliable forms of contraception for long-term pregnancy prevention.  
Long-acting, reversible contraception. Long-acting reversible contraction (LARC) is a 
class of contraception which, as the name implies, has a long duration or action and is reversible. 
There are two types of LARC: the implant and the intrauterine device (IUD), which also known 
as Intrauterine Contraception (IUC), and Intrauterine System (IUS) (Black et al., 2016). 
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An implant is a small flexible plastic rod that is inserted subdermally into the upper lateral fourth 
of the arm. There, it slowly releases a low dose of etonogestrel, a synthetic progestin that 
prevents ovulation. An implant can remain in situ for three years and removed at any time, with 
an almost immediate return to fertility (Zildar et al., 2011). Unfortunately, the implant is not 
approved for use in Canada, and it accounts for only 0.3% of the global contraception use. 
(United Nations, 2011). Since this device is inserted once and can be kept in place for many 
years, there are no opportunities for user error; so typical-use and perfect-use pregnancy rates are 
both 0.6% (Polis et al., 2016).  
  The IUD is the only LARC available in Canada. It is a small flexible polyethylene T-
shaped frame inserted into the uterus through the cervix. The procedure is straightforward, but it 
requires a clinician with the requisite skills and equipment (Bayer, 2014a). An industry-funded 
RCT by Nelson, Apter, Hauck, and Schmelter (2013) found that 96% of IUDs are inserted with a 
single attempt. Sixty-four percent of women reported little or no pain, and 8% of women only 
reported severe pain during the IUD insertion (Nelson, Apter, Hauck & Schmelter, 2013). Each 
device can remain in place for 3-10 years depending on the type, and it provides reliable 
contraception until removal. Some IUDs have a reservoir containing levonorgestrel (LNG-IUD) 
that slowly releases over several years; others, such as the copper IUD (Cu-IUD) are non-
hormonal, relying on copper as the active component. In Canada, IUDs account for less than 1% 
of contraception, which when compared to the global average of 14%, has one of the lowest rates 
of IUD use in the world (United Nations, 2011). Like the implant, once inserted, there is no 
margin for user error, so the typical-use and perfect-use pregnancy rates for IUDs are both 1.6% 
(Polis et al., 2016).  
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IUDs are wholly underutilized in Canada. Instead, most Canadians rely on oral 
contraception and condoms as their primary method of reversible contraception (United Nations, 
2011) despite recommendations by the Society of Obstetricians and Gynecologists of Canada 
(SOGC) that "health care professionals should offer IUCs as a first-line method of contraception 
to both nulliparous and multiparous women" (Black et al., 2016). It is for these reasons that I am 
focusing on identifying barriers to IUD use in Canada. My hope is that by identifying these 
barriers, we can work towards reducing them and improving access to IUDs in Canada. The end 
goal is to improve the unmet need for reliable contraception among Canadian women and help to 
prevent unplanned pregnancies.  
The Mechanism of Action of the IUD 
The dominant action of the LNG-IUD is its local progestogenic effect on the uterus; 
creating thick cervical mucous that prevents the sperm from passing through the cervical canal. 
The hormonal effects also prevent endometrial thickening, and some women may develop 
amenorrhea (Ortiz & Croxatto, 2007). An old study of only 138 women found that "fertility 
seems to be unaffected after use of an LNG-IUD" (Andersson, Batar, & Rybo, 1992, p.585. 
Despite the age of this publication and its low enrollment numbers, it appears to be the primary 
source for return-to-fertility data. More recently, a systematic review (Mansour, Gemzell-
Danielsson, Inki, & Jensen, 2011) confirmed a one-year return to fertility rate of 79-96% after 
the removal of an LNG-IUD. This is comparable to the estimated 1-year Canadian fertility rate 
of 86% (Bushnik, Cook, Yuzpe, Tough, & Collins, 2012). Despite this reassuring evidence, it is 
still possible that the LNG-IUD delay fertility for some women, though the expert consensus by 
the SOGC is that it is a safe, reliable, reversible contraceptive option (Black et al., 2016). 
Contraindications for the LNG-IUD are few. Of course, if a woman is pregnant, or if she is 
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allergic to any of the ingredients it should not be used. Additionally, if she has any hormone 
dependent cancers, fibroids that affect her uterine anatomy, current PID, or active liver disease 
(Bayer, 2014a, Bayer 2014b, Bayer 2016), they should not be used. A complete list of 
contraindications for all types of LNG-IUDs can be found in Appendix 1.  
The Cu-IUD has a very different mechanism of action. It releases copper ions into the 
luminal fluid throughout the genital tract resulting in aseptic inflammation that is toxic to the 
spermatozoa (Ortiz & Croxatto, 2007). Since the Cu-IUD is a nonhormonal contraception, it 
does not have the same progestogenic effects and therefore has fewer contraindications for its 
use. The main difference between the Cu-IUD and the LNG-IUD is that the copper device often 
results in heavier menstrual flow, while the levonorgestrel device can cause amenorrhea (Ortiz & 
Croxatto, 2007) 
For the remainder of this discussion, I will be referring to both copper and levonorgestrel 
IUDs together simply as IUDs. While each device has a distinct mechanism of actions and each 
with their clinical indications, their efficacies and function are similar; and can both be used as 
reliable contraception in Canada. 
Medical Eligibility Criteria 
Through a comprehensive review of the literature, and with extensive consultation of 
experts, the World Health Organization established medical eligibility criteria (WHO MEC) for 
each class of contraception. This criteria outlines which medically relevant condition preclude a 
woman from a particular contraceptive method. It also classifies each contraceptive method into 
one of the four categories based on this medical condition. The categories include:  
1. A condition for which there is no restriction for the use of the contraceptive method 
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2. A condition where the advantages of using the method generally outweigh the 
theoretical or proven risks 
3. A condition where the theoretical or proven risks usually outweigh the advantages of 
using the method 
4. A condition which represents an unacceptable health risk if the contraceptive method 
is used (WHO, 2015). 
For example, when considering a woman’s age, LNG-IUDs are WHO MEC category 1 
for women of all ages. Conversely, when considering a woman with active breast cancer, LNG-
IUDs are at category 4 (WHO, 2015). WHO MEC has become the standard of care for all 
providers who prescribe contraception. Anyone who prescribes these medications or who are 
involved in family planning should be familiar and comfortable with these criterions.    
A Brief History of Contraception in Canada 
Contraception in Canada was plagued with many challenges that have slowed its progress 
during the past half-century. Before 1969 it was illegal to provide hormones for contraceptive 
purposes (Liao & Dollin, 2012). Much of the early contraception research was, therefore, 
performed in Puerto Rico with fewer ethical considerations and where no laws could restrict its 
use (Rock, Pincus, & Garcia, 1956). Despite contraception being legal for the past 48 years, 
advancements have been slow. Oral contraception has improved somewhat by using new 
synthetic hormones at lower doses; the effect being fewer side effects and improved compliance. 
Surgical techniques and barrier methods have also improved during this time (Liao & Dollin, 
2012). Despite these minor advancements, contraception remains imperfect often accompanied 
with many side effects. 
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In the 1970s 10% of women relied on IUDs. These numbers fell quickly after being 
associated with severe complications (Hubacher, 2002) such as maternal death from sepsis 
(Christian, 1974), and acute PID leading to infertility (Burkman, 1981). One device caused these 
complications: The Dalkon Shield. This device had design flaws making it susceptible to 
infection and subsequently withdrawn from Canadian market in 1980's. Unfortunately, over 200 
000 women worldwide were injured from this device (Byrne, 1990) and some speculate that this 
incident caused skepticism towards all IUDs and is responsible for the current IUD rates 
(Hubacher, 2002). Since then, IUDs remained available, and modifications have been made to 
improve their safety and efficacy. 
Today are two LNG-IUDs used in Canada, the Mirena and Jaydess (Black et al., 2016). 
Health Canada has recently approved a third, the Kyleena, though it is not yet fully available 
(Government of Canada, 2017). All three LNG-IUDs are similar and are manufactured by the 
Bayer Inc. Their primary difference is their dosage of levonorgestrel. The Mirena IUD contains 
52 mg of levonorgestrel that initially delivers 20 mcg per day (Bayer, 2014a). This rate 
diminishes over time until after five years when it needs to be removed (Bayer, 2014a). The 
Jaydess IUD only contains 13.5 mg of levonorgestrel and is approved for three years (Bayer, 
2014a). The Kyleena is a low-dose IUD containing 19.5 mg of levonorgestrel, releasing 9 mcg 
per day over five years (Bayer, 2016).  
There are many different Cu-IUD options available in Canada. Bayer Inc provides the 
NovaT, Prosan Inc manufactures the Flexi-T, 7MED Industrie Inc offers the Liberte, and Besins 
Healthcare Canada Inc makes the Mona Lisa IUDs (Island Sexual Health, 2014). These brands 
are available in a variety of sizes and copper dosages, and are marketed for either nulliparous or 
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multiparous woman (Zildar et al., 2011). Regardless of the brand or IUD size, all Cu-IUDs 
function similarly and have similar indications and contraindications. 
Both copper and hormone IUDs are a reliable, safe and effective method of 
contraception. Since many Family Nurse Practitioners offer women's health services, it is 
important that Nurse Practitioners include IUDs as a contraceptive method.  
Family Nurse Practitioner 
Family Nurse Practitioners are increasing throughout Canada providing primary care for 
all populations in all stages of their life. They must, therefore, be skilled in providing a range of 
contraceptive care, and understand the full breadth of contraception options including IUDs. It is 
within the scope of a Family Nurse Practitioner to insert IUDs, however, like any advanced 
procedure, NPs must assure they have been trained "through formal theoretical and clinical 
learning" (College of Registered Nurses of British Columbia [CRNBC], 2016, p.47)  
The function of a nurse practitioner (NP) is to combine "clinical diagnostic and 
therapeutic knowledge, skills and abilities within a nursing framework that emphasize holism, 
health promotion, and partnership with individuals and families, as well as communities." 
(Canadian Nurses Association [CNA], 2009, p. 1). Furthermore, NPs are expected to identify 
issues within the health system and be a part of systems-level changes (CNA, 2016). This means 
that NPs who offer contraception management, do so in a holistic framework in collaboration 
with clients, families, and communities. It also means that if barriers exist that are impeding this 
care, that they have the responsibility to initiate changes to eliminate these barriers. It is for these 
reasons that I am directing this discussion towards NPs who, like many other primary care 
providers, are positioned where they can identify unmet need for improved contraception in 
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Canada. Furthermore, they have the responsibility to be a part of changes that can help reduce 
these barriers. 
Canada continues to have high rates of unplanned pregnancies with significant health, 
social and economic implications. Though the best method of preventing unplanned pregnancies 
is through reliable contraception, only 65% of Canadians use it (Black et al., 2015). The nine 
parameters outlined by the WHO suggest that barriers to contraception occur from 
discrimination, and/or lack of availability, accessibility, provision of information, quality 
services, privacy, participation, and accountability.  
Since IUDs are the most reliable method of reversible contraception, and they remain 
underused in Canada, I have focused this paper on a review of the literature related to barriers to 
IUD use. The goal of this literature review is to identify how Nurse Practitioners, General 
Practitioners, and other primary care providers such as Midwives can reduce barriers to IUD use 
among Canadian woman. The purpose is not to promote IUDs, but rather to identify, and work 
towards the removal of barriers to IUDs. I have made recommendations based on the findings 
from the literature and directed them towards primary care providers to help overcome these 
barriers. With this, I hope to improve informed decision making regarding contraception and all 
the available contraceptive options.    
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Chapter 2: Search Methods 
The literature was systematically searched to answer the question: how can family nurse 
practitioners reduce barriers to IUD use among Canadian women?  
Database Selection  
To focus this literature review, a search of relevant databases was achieved. A search of 
"international literature on biomedicine, including the allied health fields and the biological and 
physical sciences, humanities, and information science as they relate to medicine and health 
care" (National Library of Medicine, 2016) was performed by searching Medline, using the 
search engine Ovid. To assure no publications were missed, Medline was also searched using 
PubMed in NCBI. To "access the best and most current nursing and allied health literature" 
(EBSCOhost Research Databases, 2016), EBSCO was search using CINHAL. To explore the 
specific field of nursing education, Education Resource Information Center (ERIC) database was 
searched. Since contraception is a topic that is innately gendered, it was important to include 
publications from the field of women's studies, therefore a search of Women's Studies 
International (WSI) database was performed. Since barriers to health care are often twined with 
economics, EconLit was also. To consider the perspective of through a faith-based lens, 
publications from spiritual and religious journals were searched through The University Press 
Online database.  And finally, since no thorough literature search is complete without exploring 
systematic reviews, the evidence-based medicine (EBM) reviews database was searched. 
Medline, CINHAL, ERIC, WSI, EconLit, University Press and EBM reviews were all searched 
using similar search terms. The methods, however, varied slightly due to the variation in the 
functionality of each program used. I will first explain how each search term was selected and 
then describe how the terms were applied to each database. I will then discuss how information 
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from the gray literature was obtained. 
Search Terms 
The term Intrauterine Device was searched, and when possible the expanded MeSH 
headings or exploded terms were used. The MeSH headings and exploded terms included many 
different words used for intrauterine devices, however, neither included brand names. It is for 
this reason that additional terms were added to include specific brand names, including the two 
Canadian LNG-IUDs: Jaydess and Mirena; and the various copper IUD trade names: FlexT380+, 
LiberteTT380, Liberte UT 380, Mona Lisa 10, Mona Lisa 5, Mona Lisa N, CuT380, Flex T 300, 
Flex T 300+,and  Nova T 200.  
Since the purpose of this review is to identify barriers associated with using IUDs, 
Merriam-Webster's Thesaurus (2014) was used to determine synonyms for the term barrier. 
Synonyms included: impede, hinder, obstacle, obstruction, and restriction.  
During a preliminary review of the literature, before this systematic literature search began, a 
study by Hauck and Costescu (2015) titled Barriers and misperceptions limiting widespread use 
of intrauterine contraception among Canadian women was found. Since this study closely relates 
to my research question I used the tagged search terms from this article to identified new terms 
directly related to this topic. These new terms included Health Services Accessibility, Sex 
Education, Patient Education, and Program Evaluation. I then added these new search terms to 
each systematic search. 
Search of Medline 
To explore fields of life science and biomedical information, the database Medline was 
searched using OVID. A search for all publications containing intrauterine devices was 
completed using the broad MeSH headings. By exploding the headings, I noted that copper IUDs 
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were absent from this search. Furthermore, brand names were not included. To address these two 
shortcomings, Intrauterine devices, copper and the related MeSH terms and the Canadian IUD 
trade names were added to this search. These three searches were combined using the Boolean 
operator OR. To keep this initial search broad, no limits were placed on this search.  
The next search was conducted to identify publications related to barriers or restrictions. The 
term barrier and its synonyms were searched. Next, the new set of search terms from Hauck and 
Costescu (2015) were added using the Boolean operator, OR. Again, to keep these searches 
broad, no limits were placed on either. 
These two broad searches were then combined using the operator AND, producing over 
600 results. Limitations were then applied to restrict the publication period to the previous ten 
years. Though it may have been helpful to limit the search to publications originating in Canada, 
OVID does not permit geographical restrictions, so no further limits were applied. The resulting 
278 publications were thinned down to 31 by manually reviewing titles of each article for 
relevance. Again, these searches were reduced to 6 publications by examining their abstracts for 
relevance. I have summarized this search of Medline in Table 1. 
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Table 1 
 
Literature Search of Medline Using OVID.   
Search # Databases Search term used Limits 
applied 
Number 
of 
results 
Date searched 
(mm-dd-yyyy) 
1 MEDLINE Intrauterine Device  
MeSH headings:  
contraceptive device, 
intrauterine 
contraceptive devices, 
intrauterine 
contraceptive iud 
contraceptive iuds 
device, intrauterine 
contraceptive 
device, intrauterine 
devices, intrauterine 
contraceptive 
devices, intrauterine 
iud, contraceptive 
iud, unmedicated 
iuds, contraceptive 
intrauterine 
contraceptive device 
intrauterine 
contraceptive devices 
intrauterine device 
intrauterine devices 
unmedicated iud 
unmedicated iuds 
None 8299 11-04-2016 
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Search # Databases Search term used Limits 
applied 
Number 
of 
results 
Date searched 
(mm-dd-yyyy) 
2 MEDLINE Intrauterine devices, copper 
MeSH headings:  
copper intrauterine device 
copper intrauterine devices 
copper releasing iud 
copper-releasing iud 
copper-releasing iuds 
device, copper intrauterine 
devices, copper intrauterine 
iud, copper releasing 
iud, copper-releasing 
iuds, copper-releasing 
intrauterine device, copper 
intrauterine devices, copper 
None 1830 11-04-2016 
3 MEDLINE Mirena OR Jaydess OR 
FlexT* OR Liberte* OR 
Mona Lisa OR CuT380 OR 
Nova T 200 
None 779 11-04-2016 
4 MEDLINE Impede synonyms: 
Impede* OR hinder OR 
Barrier* OR obstacle* OR 
obstruct* OR restrict*  
None 920 000 11-04-2016 
5 MEDLINE Health Services Accessibility 
OR Sex Education OR Patient 
Education as a Topic OR 
Program Evaluation 
None 1.09 M 11-04-2016 
6 MEDLINE (1 OR 2 OR 3) AND (4 OR 
5) 
Publication 
dates 2006-
2016 
278 11-04-2016 
 
Search of PubMed 
To ensure a thorough search of the biomedical literature, Pubmed was searched using 
NCBI. I applied the same search methods, and terms used to search Medline in OVID described 
above. Of the 504 results, 66 were found to have appropriate titles. I reviewed their abstracts, and 
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45 were found to be directly related to the research question. Of these, all but one had already 
been previously identified by searching Medline, suggesting that saturation of the searches 
within PubMed and Medline was achieved. 
Table 2 
Literature Search of PubMed using NCBI. 
Search # Databases Search term used Limits applied Number 
of results 
Date searched 
(mm-dd-yyyy) 
1 PubMed Intrauterine Device  
Exploded terms:  
Contraceptive Devices, 
Intrauterine; IUD; Pessaries, 
Intracervical; Pessaries, 
Intrauterine; Intrauterine 
Device; Contraceptive 
Device, Intrauterine; IUDs; 
Pessary Intracervical; Pessary 
Intrauterine  
none 12 565 11-04-2016 
2 PubMed Mirena OR Jaydess OR 
FlexT* OR Liberte* OR 
Mona Lisa OR CuT380 OR 
Nova T 200 
None 6014 11-04-2016 
3 PubMed Impede synonyms: 
Impede* OR hinder OR 
Barrier* OR obstacle* OR 
obstruct* OR restrict* 
None 1.01M 11-04-2016 
4 PubMed Health Services Accessibility 
OR Sex Education OR Patient 
Education OR Program 
Evaluation 
None 203 000 11-04-2016 
5 PubMed (1 OR 2) AND (3 OR 4) Publication 
dates 2006-
2016 
504 11-04-2016 
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Search of CINAHL 
To search fields of nursing, allied health, biomedicine and healthcare, similar terms 
previously applied to PubMed and Medline were used to search CINAHL. Minor differences in 
this search arose due to subtle differences in the EBSCOhost program. Search 1 included the 
exploded terms of intrauterine device, which is defined by CINHAL as "mechanical devices 
inserted into the uterine cavity for contraceptive purposes" (EBSCOhost Research Databases, 
2016). Search 2 was added to include the brand names of the Canadian hormone releasing 
intrauterine devices. Search 3 included the synonyms of barrier, and search 4 included the new 
search terms from Hauck and Costescu (2015). This search produced 290 results, which was then 
reduced by limiting publications from the past 10 years. The title of each publication was 
screened for relevance, and the remaining were sifted by reviewing the abstracts. The resulting 
12 publications were identified as relevant, of them, 6 were unique to this search.  
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Table 3 
 
Literature Search of CINAHL using EBSCOhost. 
Search # Databases Search term used Limits applied Number of 
results 
Date searched 
(mm-dd-yyyy) 
1 CINAHL 
complete 
Intrauterine Device  
Exploded terms:  
Contraceptive Devices, 
Intrauterine; IUD; 
Pessaries, Intracervical; 
Pessaries, Intrauterine; 
Intrauterine Device; 
Contraceptive Device, 
Intrauterine; IUDs; 
Pessary Intracervical; 
Pessary Intrauterine  
 
none 2381 11-24-2016 
2 CINAHL 
complete 
Mirena OR Jaydess OR 
FlexT* OR Liberte* OR 
Mona Lisa OR CuT380 
OR Nova T 200 
None 189 11-24-2016 
3 CINAHL 
complete 
Impede synonyms: 
Impede* OR hinder OR 
Barrier* OR obstacle* OR 
obstruct* OR restrict* 
None 142 000 11-24-2016 
4 CINAHL 
complete 
“Health Services 
Accessibility” OR “Sex 
Education” OR “Patient 
Education” OR “Program 
Evaluation” 
None 92 000 11-24-2016 
5 CINHL 
complete 
(1 OR 2) AND (3 OR 4) Publication 
dates 2006-
2016 
185 11-24-2016 
 
Search of Other Databases 
EconLit, ERIC, and WSI were all searched using EBSCOhost using the same search 
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terms. Table 4 summarizes this search. The resulting 154 publications were sifted for relevance, 
and 14 novel publications were identified.  The University Press Online was searched using the 
same search terms and method, and a single paper-based publication was identified. 
Table 4 
Literature Search of EconLit, ERIC and Women’s Studies International using EBSCOhost. 
Search # Databases Search term used Limits 
applied 
Number of 
results 
Date searched 
(mm-dd-yyyy) 
1 EconLit,  
ERIC,  
Women’s 
Studies 
Internatio
nal   
Intrauterine Device none 1053 12-01-2016 
2 EconLit,  
ERIC,  
Women’s 
Studies 
Internatio
nal   
Mirena OR Jaydess OR 
FlexT* OR Liberte* OR 
Mona Lisa OR CuT380 OR 
Nova T 200 
 
None 485 12-01-2016 
3 EconLit,  
ERIC,  
Women’s 
Studies 
Internatio
nal   
Impede* OR hinder OR 
Barrier* OR obstacle* OR 
obstruct* OR restrict* 
None 114 000 12-01-2016 
4 EconLit,  
ERIC,  
Women’s 
Studies 
Internatio
nal   
Health Services 
Accessibility OR Sex 
Education OR Patient 
Education OR Program 
Evaluation 
None 62 000 12-01-2016 
5 EconLit,  
ERIC,  
Women’s 
Studies 
Internatio
nal   
(1 OR 2) AND (3 OR 4) Publicatio
n dates 
2006-2016 
154 12-01-2016 
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Search the Evidence Based Medicine Reviews 
Since the EBM Reviews database uses OVID, the same search method used to search 
Medline was employed. The titles and abstracts of the resulting 146 publications were reviewed, 
15 were identified as relevant, and only 5 were unique. The other 10 had been previously 
identified during prior searches. This suggests that our searches reached a satisfactory level of 
saturation. Details from this search are summarized in table 5. 
Table 5 
 
Literature Search of EBM reviews using OVID. 
Search # Databases Search term used Limits 
applied 
Number 
of 
results 
Date 
searched 
(dd/mm/yy) 
1 All EBM 
Reviews 
Intrauterine Device OR IUD 
OR Jaydess OR mirena OR 
Copper-T 
None 866 All 
2 All EBM 
Reviews 
Impede* OR hinder OR 
Barrier* OR obstacle* OR 
obstruct* OR restrict* 
None 60 900 All 
3 All EBM 
Reviews 
Health Services Accessibility 
OR Sex Education OR Patient 
Education OR Program 
Evaluation 
None 16 167 All 
6 All EBM 
Reviews 
1 AND (2 OR 3) None 146 2006-2016 
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Searching Beyond Databases 
In addition to searching databases for peer reviewed literature, a search of community 
resources, national and international data, and drug monographs was also performed. These 
independent websites searched are summarized in table 6. 
Table 6 
 
Website Searches of Community Resources, National Data and Drug Information. 
Name of Organization Website Information acquired 
The Options for 
Sexual Health  
 
https://www.optionsforsexu
alhealth.org 
Current, local, contraceptive 
resources. 
Canadian Public 
Health Association 
 
http://www.cpha.ca  History of contraception and sexual 
health in Canada. 
Canadian Institute for 
Health Information 
http://www.cihi.ca Canadian-specific pregnancy 
information, particularly focusing on 
unplanned pregnancy rates 
World Health 
Organization 
http://www.who.int 1. WHO MEC criteria  
2. international contraceptive rates  
Non-Insured Health 
Benefits  
http://www.healthycanadia
ns.gc.ca 
Contraception insurance coverage for 
those under the NIHB plan 
Student Health 
insurance benefits 
http://studentcare.ca/ Contraception insurance coverage for 
those under the NIHB plan 
Bayer Inc. http://omr.bayer.ca Canadian drug monographs for IUDs. 
Reddit https://www.reddit.com/r/T
woXChromosomes/ 
Online, open source, public dialogue. 
 
To broaden the data, I expanded the collection to include informal sources such as face to 
face discussions and online discussion boards. Face to face discussions occurred with Physicians, 
Nurse Practitioners, a Midwife and a Pharmacist. The topics of these conversations included 
their professional and personal perceptions on IUDs, as well as their impressions on barriers that 
woman face obtaining them. Additionally, we discussed strategies to reduce some of these 
barriers, focusing on training opportunities that each professional received during their initial 
training and as continued medical education.  
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To learn of the public discourse about IUDs I searched the American social news 
aggregation: Reddit. Within Reddit, there is a popular sub-Reddit titled TwoXChromosomes; a 
forum specifically “intended for women’s perspectives” (Reddit, 2017). TwoXChromosomes has 
over ten million active followers and contains dozens of discussions pertaining specifically to 
IUDs, each with hundreds of comments read by thousands of individuals. Reddit is a popular 
platform for individuals to openly discuss their personal experiences with IUDs and therefore it 
was a valuable resource to gather unfiltered and unmoderated information. In reading these 
posts, I obtained a unique perspective into the public understanding and dialogue of IUDs. These 
perspectives allowed me to have an improved understanding of personal lived experiences of 
women with IUDs. One caveat to these online forums is that they do not wholly represent the 
IUD experience, they merely provide insight into those which are chosen to be shared. Thus, 
these online discussions tend to be biased towards the extremes. Despite this bias, I was 
surprised to learn that many of these experiences were positive, and much of the shared 
information was accurate. I have included a rather small collection of excerpts from this Reddit 
forum in Appendix 2.  
Appraisal of the Evidence 
Five meta-analyses that had been retrieved from these searches were analyzed using the 
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (Moher, 
Liberati, Tetzlaff, Altman, & Group, 2009). I modified the PRISMA criteria and created a 
checklist for this process. The modified PRISMA checklist is found in Appendix 3. During this 
analysis, two of the five meta-analyses were found to be from the same data set. The meta-
analysis by Arrowsmith, Aicken, Majeed, and Saxena (2012) was published in Contraception, 
and turned out to be the same meta-analysis used in their Cochrane Review (Arrowsmith, 
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Aicken, Saxena, & Majeed, 2012). Both these publications drew the same conclusion from the 
same data set. I was, therefore, cautious not to interpret them as unique studies. Instead, for this 
literature review, I treated them as a single study. 
The remaining studies were appraised using the Critical Appraisal Skills Program 
(CASP), an evaluation technique that had initially been presented by Oxman et al., (1994). The 
CASP appraisal checklist has been modified, and specific versions were developed for 
Randomized Control Trials, Case Control Studies, Cohort Studies, and Qualitative Research 
(Critical Appraisal Skills Programme, 2017a; Critical Appraisal Skills Programme, 2017b; 
Critical Appraisal Skills Programme, 2017c; Critical Appraisal Skills Programme, 2017d). A 
simplified version of these checklists are found in Appendices 4-7.  
Summary of Methods 
Overall, the quality of these studies was good; however, they had significant industry 
influence. Both the PRISMA and CASP appraisal tools helped guide the appraisal of each study, 
which is discussed in more detail in the Findings section in Chapter 3. 
The data obtained from the 32 publications retrieved in this search will make up the 
evidence used for the Findings and Recommendations sections in Chapters 3-4. I am not 
claiming that this search was exhaustive or comprehensive, however, due to the repeat and 
redundant results found in each search, I am satisfied that these search methods achieved 
sufficient saturation and that an accurate representation of the literature was obtained.  I am, 
therefore confident that this search was sufficiently thorough in delivering conclusive results, 
which can guide me towards making evidence-based recommendations. The following two 
chapters will present these findings and make recommendations based on this data.   
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Chapter 3: Findings 
A meta-analysis by Hauck and Costescu (2015) categorized the barriers that Canadian 
women face obtaining IUDs into three broad categories:  
1. professionals who are providing contraception counseling and prescribing 
contraceptive methods: Health care Providers (HCPs),   
2. women who are seeking or who would benefit from contraception: contraception 
users, and 
3. organizational structures in which healthcare and pharmaceuticals are delivered: the 
healthcare system.  
I have used these three categories as a theoretical framework to discuss my findings throughout 
this chapter. I have used these findings to build the recommendations presented in the discussion 
in Chapter 4.   
Barrier 1: Health Care Provider 
Contraception such as condoms, spermicides, diaphragms, and caps are readily available 
through drug stores and community health services without the need for a prescription. Other 
traditional methods such as family planning and withdrawal can be learned and achieved 
independently. The advantage of these methods is that they can be obtained independently, and 
do not require an HCP. The disadvantage is that when they are used alone, they have high 
typical-use failure rates and cannot be relied on as a sole means to prevent pregnancies. 
Alternatively, more effective contraceptive methods such as oral and implantable hormones, and 
surgical sterilization are more reliable; however, they depend on an HCP to provide them. This 
dependence can limit availability, as it relies on the knowledge, skills, training, abilities, beliefs, 
and biases of the HCP. IUDs are especially dependent on HCPs for both the prescription and the 
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insertion of each device. This dependence can act as a barrier to acquiring them. Poor provider 
knowledge about IUDs, and a lack of training in their insertion have been shown to inhibit IUD 
use (Black, Lotke, Buhling & Zite, 2012; Black, Lotke, Lira, Peers & Zite, 2013; Buhling, 
Hauck, Dermout, Ardaens & Marions, 2014; Stubbs & Schamp, 2008) 
Consistent and accurate knowledge is vital for contraceptive counseling by instilling trust 
in the provider (Dehlendorf, Levy, Ruskin, & Steinauer, 2010). The choice of language used to 
communicate this knowledge can also impact this trust (Belfield, 2010). For example, some 
providers use the term, long-acting reversible contraception (LARC), to describe all IUDs and 
implants, with the thought that LARC implies efficacy and reversibility. Some women, however, 
are concerned with this term, understanding that it may create a prolonged time of return to 
fertility (Glasier, Scorer, & Bigrigg, 2008). We need to assure that healthcare providers 
understand IUDs, and use language that is well understood by their patients. 
Provider knowledge. A woman seeking contraceptive advice from her HCP is especially 
vulnerable to her provider’s knowledge, as her provider will only advise on methods with which 
they are familiar. Poor IUD knowledge among HPCs can be broad, varied, and provider 
dependent. A small Canadian survey of 131 physicians with a response rate of 81% found that 
more than 60% of GPs believed that pelvic inflammatory disease and ectopic pregnancies were 
significant risks associated with IUDs. Furthermore, they found that over 70% of physicians 
would not recommend an IUD to a nulliparous woman (Stubbs & Schamp, 2008). This is despite 
recommendations from the SOGC that “Health care professionals should offer IUCs as a first-
line method of contraception to both nulliparous and multiparous women” (Black et al., 2016, 
p.183). It has been suggested by Stubbs and Schamp (2008) that this inaccuracy of perceived risk 
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arises from providers having poor knowledge of the World Health Organization Medical 
Eligibility for Contraception (WHO MEC) criteria.  
Black et al., (2013) asked 1862 HCPs about their beliefs and practices around IUDs in 
nulliparous women. They found that only 15% of respondents correctly identified nulliparity as 
WHO MEC category 1, and 23% replied that they did not know. The remaining 62% incorrectly 
assigned nulliparous women into lower eligibility.  
Similarly, Buhling et al. (2014) surveyed 1103 HCPs and found that most providers were 
unable to correctly assign WHO MEC categories, mainly overestimating the risk associated with 
nulliparity and pelvic inflammatory disease. Unfortunately, the 1103 providers from this survey 
only represented a response rate of 15%, and only 100 of the participants were Canadian. 
Furthermore, the inclusion criteria for this study required that participants see more than 20 
women per month for contraception counseling. These characteristics of this study limit its 
generalizability, especially in low volume, rural, Canadian clinics. Despite this limitation, the 
conclusions from Black et al. (2013), Buhling et al. (2014), and Stubbs and Schamp (2008) are 
evident; providers require improved education about the WHO MEC criteria, particularly for 
nulliparous women.   
Difficulty with IUD insertion. Fear of a difficult IUD insertion is yet another reason 
HCPs may hesitate to recommend an IUD. In an industry funded systematic review looking at 
factors affecting IUD use among nulliparous women, Black et al. (2012) found that many HCPs 
associate nulliparity with a more difficult IUD insertion. This is despite strong evidence that 
parity has no effect on the difficulty of the insertion (Kaislasuo, Heikinheimo, Lähteenmäki, & 
Suhonen, 2014). This review concluded that IUD rates could increase if we were to improve the 
knowledge of insertion difficulty among HCPs (Black et al., 2012). Though this systematic 
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review did not include Canadian data, it did show a trend among many developed nations; that 
providers often incorrectly anticipate difficult IUD insertions. It is, therefore reasonable to infer 
that Canadian HCPs would also benefit from improved knowledge and skill managing difficult 
IUD insertions.   
Excessive perception of risks. An online survey by Black et al. (2013) compared the 
perceived risk of IUDs among health care providers. They found that more experienced HCPs 
tended to incorrectly associate higher rates of PID and infertility with IUDs than their colleagues 
with less than 10 years of experience. Interestingly, similar results were found by Dehlendorf et 
al. (2010) who used a convenience sample of 524 health care providers (Nurse Practitioners, 
Physicians, and Physician Assistants) and found that many providers incorrectly associated 
infertility and PID with IUDs. Through a multivariate analysis, Dehlendorf et al. (2010) found 
that younger, female, and obs/gyne specialists tended to have more have more updated 
contraception knowledge, and were less likely to incorrectly associate IUDs with PID and 
infertility.  
There are a few suggestions that can account the difference between experienced and less 
experienced providers. First, experienced providers tended to be older, and it is possible the 
tarnished reputation of IUDs caused by the infamous Dalkon shield of the 1960s persists in their 
memory. Secondly, it was suggested that newly trained Nurse Practitioners and medical residents 
are receiving improved IUD-specific training resulting in a better understanding of the risks 
associated with IUDs (E. Kruithof, personal communications, December 12, 2017). Though 
training is improving, and new providers are becoming more knowledgeable about IUDs, 
misinformation persists among providers, and educational initiatives need to be made.  
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Concern for pain. Misperceptions about IUDs among healthcare providers extend 
beyond nulliparous women, PID, and infertility. Understandably, providers are also concerned 
about inflicting pain on their patients. This concern can precipitate hesitance to recommend them 
(Buhling et al., 2014). The concern for pain with IUD insertion can propagate from the provider 
to the patient, and may further impact a woman’s choice for an IUD. We can not ignore pain 
caused by an IUD insertion, as it is a reality for many women. In an extensive review of the 
online Reddit forum, many women feared pain leading up to their IUD insertion (Aldona, 2017). 
Though pain associated with this process varies among women, Black et al. (2012) found that it 
is often over-anticipated. By becoming properly informed, providers can set realistic 
expectations concerning pain caused by this procedure. Furthermore, HCPs should learn 
effective techniques for pain control to help reduce it.  
Misunderstanding the mechanism of action. The systematic review by Black et al. 
(2012) also found that some providers misunderstand the mechanism of action of the IUD, 
believing that it prevents the implantation of a fertilized ovum. Similarly, in a randomized 
anonymous survey of 1100 European women, Lopez-del Burgo et al., (2012) found that many 
women believed IUDs to function as an abortifacient. Both HCPs and IUD users who believe 
that life begins at conception may determine it unethical to use a form of contraception that 
terminates a zygote. This belief persists despite a well-known mechanism of action in both the 
Cu-IUD and LNG-IUDs; that is, they act to prevent fertilization rather than preventing 
implantation (Ohly & Westhoff, 2015; Ortiz & Croxatto, 2007). Assuring that HCPs have an 
accurate understanding of this mechanism of action would help prevent the propagation of this 
misinformation. 
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Barrier 2: The IUD Users 
In addition to misinformed HCPs, barriers to IUDs can also originate from 
misinformation among contraceptive users themselves. Misinformation can propagate among 
users and lead to poor public knowledge and poor IUD acceptance (Gomez, Hartofelis, 
Finlayson & Clark, 2015; Hall et al., 2016; Hauck & Costescu, 2015; Rubin & Winrob, 2010; 
Secura, Allsworth, Madden, Mullersman & Peipert, 2010).  
Public knowledge. A large online multi item survey of 1892 American female 
undergraduate students assessed the knowledge and personal experiences with long acting 
reversible contraception (Hall et al., 2016). This survey found that 79% of women self-identify 
as having “little” or “no” knowledge about IUDs, and that this lack of knowledge, whether 
perceived or real, was correlated with women not choosing the IUD. The primary weakeness of 
this survey is that it restricted its sample population to post-secondary attendees. Though this 
limited sample makes the results difficult to generalize, it does indicate that well-educated 
women have poor IUD knowledge. Additionally, this survey had a meager response rate; 13000 
surveys were sent out, and only 1892 responded, a response rate of 14%. This study did not 
address this low response rate nor did it perform demographic analyses of the 1892 respondents 
to see if they were statistically different than the initial 13000 sample. Despite these 
shortcomings, strength in this study resides in its multivariate analysis of several subpopulations. 
This study found even poorer IUD knowledge amongst ethnic minorities, unemployed women, 
those living on campus, and women of mothers with low education. Though this study was 
entirely American, it is reasonable to predict that these same subpopulations could have similar 
levels of IUD knowledge in other countries such as Canada.  
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Poor IUD knowledge was identified during a qualitative study involving Scottish women 
aged 16-24 (Okpo, Allerton & Brechin, 2014). A lack of IUD knowledge was demonstrated by 
many women, one of which, after being asked what she knew about long acting reversible 
contraception, replied: “Is that a hysterectomy?” (Okpo et al., 2014, p. 936). Rubin and Winrob 
(2010) also conducted a qualitative study with semi-structured interviews among women who 
self-identified as having some information about IUDs. Even among this select population, many 
knowledge gaps were identified.  
Many HCPs report that a common concern among women is that IUDs may interfere 
with their long-term fertility. This was found through my communications with various HCPs 
(K. Black, personal communications, March 26, 2017; H. Dunbar, personal communications, 
April 12, 2017; E. Kruithof, personal communications, December 10, 2016). Gomez et al. (2015) 
also found that women were concerned about the return to fertility with IUDs. This concern 
persists despite a well-documented 1-year pregnancy rate of up to 96% after IUD discontinuation 
(Mansour, Gemzell-Danielsson, Inki, & Jensen, 2011). This confirms yet another area where a 
lack of user knowledge may act as a barrier IUD contraception.  
Sources of contraceptive information. We cannot rely solely on HCPs to provide 
contraceptive education. In the Scottish qualitative study discussed above, Okpo et al. (2014) 
found that most contraceptive knowledge came through friends and family, and that women 
tended to rely on their GP solely to acquire the prescription for this contraception. They found 
that many women had already made up their minds on their method of contraception before the 
medical appointment. These women felt that their GPs did not have time to discuss it; and that 
most were male and would not understand their values (Okpo et al., 2014).  
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This was reiterated in an online American survey of 1154 University women by Gomez 
et al. (2015) who found that only 35% of contraception users received their information from an 
HCP. Instead, most of their information came from friends, the internet, and the TV. Due to this 
large variety of sources, and knowing that the most contraceptive information does not come 
from HCPs, we need to ensure that public education is accurate, accessible and available in the 
community.  
Personal values. It is crucial that personal values and beliefs are considered when 
choosing any method of contraception. The qualitative study by Rubin and Winrob (2010) found 
that many women were unsettled by having a device sitting inside them for many years. This 
sentiment was confirmed in an anonymous online survey by Hall et al. (2016) who found that 
44% of female university students did not want a foreign object in their body. Gomez et al. 
(2015) agreed that many women found the idea of an IUD to be “unattractive because they 
disliked the idea of a device in their bodies” (p.7). Though these three studies agreed that many 
women were uncomfortable with the thought of a foreign object inside of them, none of these 
studies could determine that magnitude that this discomfort would have in deterring a woman 
from selecting an IUD.  
Several studies have also found that many women prefer having personal control in 
deciding when to initiate or terminate their contraception (Gomez et al., 2015; Hall et al., 2016; 
Rubin & Winrob, 2010). Lack of personal control is a fundamental disadvantage to the IUD as it 
can only be inserted or removed by a skilled provider. Another personal value to consider is that 
some women prefer to retain their menses, as some women are reassured by monthly 
menstruation confirming that they are not pregnant (Rubin & Winrob, 2010). This is important 
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when selecting which IUD to choose since the Mirena has a higher propensity for causing 
amenorrhea than any of the copper IUDs (Zildar et al., 2011).  
These personal values are important considerations. Though the effect will vary with 
each person, they should always be considered. Making sure that women are well informed, with 
accurate information tailored to their needs is at the heart of reducing barriers to IUDs while 
honoring personal values. 
Barrier 3: System-level barriers 
The third barrier affecting IUD use is at health care system level (Hauck & Costescu, 
2016). In this section, I will discuss how the current structure of our health care system can 
impede IUD use.  
Personal cost. In Canada, the out-of-pocket cost for an IUD will depend on which device 
is selected, and individual’s insurance coverage. For example, most women attending university 
have 80% coverage of medications (Student Care, 2017) and therefore incur a minimal cost. 
Other women, however, with no extended insurance can expect to pay $52-350 depending on the 
IUD that they choose (Island Sexual Health, 2014). Fortunately, in Canada, the cost for a 
clinician to insert the device is paid by our medical services plan. That is if a woman can find an 
HCP with the requisite knowledge and skills to provide this service. Since not all providers have 
these skills, a woman may need to travel to have this done. The personal out of pocket costs for 
the IUD, coupled with the potential cost of the trip may very likely be a barrier for some woman, 
particularly for those in rural and remote areas who may have to travel long distances. It is, 
therefore, much cheaper and simpler to choose the pill or injectable progestin, both of which can 
be administered easily.   
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Since IUDs are expensive it is important to consider how this may affect their use. The 
contraceptive CHOICE study was a large prospective cohort trial that looked at the effect that 
personal cost has on IUD selection, furthermore it demonstrated a system-level strategy that 
could be used to reduce this barrier (Secura et al., 2010). This study recruited almost 10 000 
American women ages 14-45 years. The inclusion criteria were woman who identified as either 
being dissatisfied with their current contraceptive method, or wanting to initiate contraception; 
and who wanted to prevent a pregnancy for at least 1 year. This experiment offered women an 
opportunity to change their contraceptive method, accompanied by brief appropriate counseling, 
at no cost. The objective was to see which method would be preferred if cost was eliminated. 
They found that 56% of participants switched their contraception to IUDs, which when 
compared to the national American average of 3% (United Nations, 2011), is quite remarkable. 
In addition to removing financial barriers, the authors discussed other contributing factors to this 
high IUD uptake. First, in addition to their contraception, each participant was also provided 
with a standardized counseling of all contraceptive methods. It is possible that this process 
helped to dispel some of the rumors about IUDs that may have persisted amongst participants. 
Secondly, all contraception was offered equally regardless of age, parity, or history of STIs 
which may also have helped to dispel misinformation about IUDs. Secura et al. (2010) conclude 
that by eliminating cost, providing standardized contraceptive information, and by offering all 
contraceptive methods equally, that many women will preferentially choose IUDs. One 
important consideration that may have biased these results is that the inclusion criteria selected 
for women who were already dissatisfied with their current method of contraception. This may 
have favored women who already have an interest in IUDs. The strengths of this trial, however, 
are found in its simple methodology making the principle simple to understand, and in its large 
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sample size making it generalizable to an American population. For our purposes, however, its 
applicability to Canadians could be questioned. I argue, however, that American and Canadian 
cultures and values are not remarkably different, so applying these results to a Canadian 
population is not unreasonable.  
The cost to the system. Two large studies, one American and one British, looked at the 
cost benefit of providing government funded contraception. In doing so, these studies 
demonstrated how the funding schemes of our health care systems might be acting as barriers to 
IUDs.  
The Iowa initiative was an American project performed in 2007 that presented a benefit-
cost analysis for publically funded family planning services (Udeh, Losech & Spies, 2009). This 
study estimated the cost of publically funded family planning (counseling and contraception) and 
compared it to the savings acquired from preventing unplanned pregnancies. This analysis 
focused on individuals living in Iowa who were receiving social assistance and public health 
care; a population for whom an unplanned pregnancy would increase the demand on public 
services. Udeh et al. (2009) found that for every dollar spent on family planning services, three 
dollars would be saved within one year. This savings grew when LARCs such as IUDs were 
used, as their one-time cost remains effective for multiple years. This study demonstrates that 
government level initiatives can improve IUD use by removing the barrier of cost through 
system-wide initiatives.   
The limitations of this analysis are significant. First, it is especially difficult to predict the 
actual financial cost of an unintended pregnancy. It is for this reason that Udeh et al. (2009) 
simplified matters by only including expenses incurred from prenatal, delivery, antenatal 
services, and pediatric services for the first 5 years of the child’s life. They did not include other 
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potential costs associated with complicated pregnancies, abortions, adoptions, or other possible 
pregnancy outcomes. This analysis, is, therefore, an underestimate of these benefits. A second 
limitation of this study is its focus on Iowa, a Midwestern American state. Despite this, I will 
suggest that since this study looked at low-income Iowa residents receiving social assistance and 
publically funded health care, that this population resembles Canadian citizens in that Canadians 
also receive publically funded health services. We can, therefore, carefully extrapolate that 
Canadians may also benefit fiscally from publically funded family planning services.  
In a prospective cohort review of 283 British women, Cook and Flemming (2014) 
analyzed the long-term savings achieved by using long acting contraception. They found that the 
average length of IUD use was 3.44 years, resulting in an annual cost of £54. This price was 
found to be almost ten times cheaper than other forms of reliable contraception such as oral 
contraception and the progestin injections. Cost savings were attributed to the need for fewer 
clinic visits and the one-time cost of the contraception itself. Unfortunately, Cook and Flemming 
(2014) did not publish whole numbers comparing the costs of contraceptive methods. This makes 
it difficult to generalize these savings to other countries. Furthermore, the variability of 
pharmaceutical costs and providers’ wages amongst countries makes it difficult to apply these 
results to a Canadian setting. Since Britain and Canada both have single-payer, publically funded 
health care systems, it is reasonable to conclude that Canadian women could also save money by 
using IUDs.  
Both the Iowa initiative by Udeh et al. (2009); and the British Study by Cook and 
Flemming (2014) demonstrated that publically funded long-acting contraception could reduce 
system-wide barriers. Furthermore, a publically funded initiative can see system-wide cost 
savings in the long run 
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Product labeling. In Canada, there are two commonly used hormone-releasing IUDs 
available: the Mirena and the Jaydess, both of which are Bayer products. The Mirena delivers 
52mg of levonorgestrel which is released over 5 years, while the Jaydess offers a lower 
levonorgestrel dose over 3 years. The Canadian Mirena drug monograph states “MIRENA is not 
the contraceptive method of first choice for young, nulligravid women” (Bayer®, 2014a, p.12). 
The Jaydess drug monograph, on the other hand, makes no reference to nulliparity only stating 
that “Safety and efficacy has been studied in women aged 18 and over” (Bayer®, 2014b, p.12). 
This discordance in product labeling exists despite both devices being safe for nulliparous 
women (Eisenberg et al., 2015). This inconsistency among product labels may introduce 
uncertainty and confusion among providers and the public when choosing a contraceptive 
method, and this confusion may be a barrier to IUD use.  
Requirement for multiple office visits. The nature of IUDs is that they often require at 
least two separate medical office visits before the contraception is delivered. The first visit often 
involves counseling and providing the prescription for the IUD. And the second clinic visit, after 
picking up the IUD from the pharmacy, is to have the device inserted. A unique retrospective 
database review in an urban American clinic looked at the effect of this two-visit requirement, 
and the impact it has on IUD rates (Bergin, Tristan, Terplan, Gilliam & Whitaker, 2012). These 
authors found that of the 708 women who requested IUDs, fewer than half returned to have them 
inserted. Could requiring a second visit for the insertion act as a barrier to the IUD? Perhaps. 
Alternately, we must consider that this second clinic visit served as a buffer by providing women 
with an opportunity to reflect and reconsider their contraceptive choice. In a subset analysis, 
however, Bergin et al. (2012) found a correlation between the distance that women lived from 
their clinic and the likelihood that they would return and have the IUD inserted. They found that 
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those who lived farther from their clinic were less likely to go back to have it inserted. Since this 
analysis was a retrospective review, it's challenging to determine causality. Despite this, we must 
remain cognoscente of how repeat office visits for IUD insertions, especially for those who live 
far from the clinic, may act as a barrier to IUD use.    
Summary of Findings 
Multiple barriers to IUDs were identified. First, many health care providers lack 
knowledge about IUDs particularly regarding their eligibility criteria and their associated risks. 
This lack of knowledge may reduce the number of women for whom IUDs are recommended. 
Second, many women seeking contraception have a misunderstanding about IUDs and are 
receiving their information from non-healthcare sources. And third, the health system contains 
barriers that impede IUD use such as high cost, poor product labeling, and the necessity of 
multiple office visits. In the following chapter I will discuss recommendations that can be used to 
reduce these barriers.  
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Chapter 4: Discussion and Recommendations  
Reducing barriers to IUD use among Canadian women is a vast undertaking. It requires 
buy-in and action from the public and health care stakeholders, as well as changes at educational, 
political, and economic levels. The discussion that follows is a collection of recommendations 
that arose from this research. These recommendations are not a final solution, but rather a small 
step forward towards helping to address this issue. These recommendations focus on how family 
nurse practitioners can contribute to this effort by reducing barriers to IUD use among Canadian 
women with the goal of reducing unplanned pregnancies. Barriers to IUDs in the previous 
chapter were organized into three categories: those associated with health care providers, the 
IUD user, and the healthcare system. The following discussion of recommendations will follow 
the same structure. 
Recommendations For Healthcare Providers 
A lack of contraceptive education among healthcare providers, particularly about IUDs, 
has been identified as a barrier to Canadian women obtaining them (Black et al., 2012; Buhling 
et al., 2014; Hauck & Costescu, 2015; Secura et al., 2010; Stubbs & Schamp, 2008). An 
Australian study found that with increased training opportunities, providers increased their 
knowledge, which in turn increased IUD prescriptions (Stewart, Digiusto, Bateson, South, & 
Black et al., 2016). The role of the Nurse Practitioner in British Columbia is to act “as a change 
agent through knowledge translation and dissemination of new knowledge” to provide leadership 
in clinical care, and as a resource person, educator and role model (CRNBC, 2015, p.15). This 
excerpt from the College highlights the public expectation that NPs be involved in ongoing 
scholarship and curriculum changes to promote evidence-based education. Education reform 
should focus on improving the understanding of the IUDs such as their indications and 
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contraindications; training of insertion techniques; and assessing and rectifying insertion and 
post-insertion complications. 
Improving IUD understanding.  Choosing language that is consistent and unambiguous 
to communicate information about intrauterine contraception is crucial when providing 
contraceptive counseling (Belfield, 2010). This includes using a single term for these devices and 
avoiding catch-all terms such as Long Acting Reversible Contraception. Doing so would reduce 
confusion and improve public understanding (Glasier et al., 2008).  
The concern of inflicting pain on patients has been identified as a reason that IUDs are 
not recommended by GPs (Buhling et al., 2014). Additionally, Kaislasuo, Heikinheimo, 
Lähteenmäki, and Suhonen (2014) found that “pain was commonly assessed one step milder by 
the physician than the woman” (p. 6). In this study, physicians reported that 23% of their 
insertions caused severe pain, however, none of their insertions were intolerable. This perceived 
pain was entirely different from the women's’ report of pain whereby 58% of women described 
insertions as being either severe or intolerable (Kaislasuo et al., 2014). This discrepancy 
highlights that pain is an ongoing challenge with IUD insertion, often underestimated by HCPs.  
These studies demonstrate the importance of proper pain control techniques such as 
premedication with NSAIDS and the use of a cervical lidocaine block (Lopez et al., 2015). It is 
vital that Nurse Practitioners incorporate evidence-based analgesic techniques into their practice 
when inserting IUDs. Furthermore, it is essential that Nurse Practitioners engage in ongoing 
research to improve these analgesia strategies. This ongoing challenge to control pain reminds us 
to remain patient-centered by establishing realistic expectations for pain, so women are not 
surprised by the discomfort that it causes. (Buhling et al., 2014). 
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In addition to pain, many providers are worried about difficult insertions (da Silva-Filho, 
Lira, Rocha & Carneiro, 2016).  Since there are few parameters to predict a difficult insertion 
(Kaislasuo et al., 2014), many HCPs may hesitate to recommend them. There are few predictors 
for a painful and challenging IUD insertion, and this uncertainty causes reluctance among HCPs 
to offer them. This uncertainty highlights a need for improved training opportunities to problem 
solve difficult insertions, and to learn proper techniques for pain control. Furthermore, system-
wide changes should be made to improve timely referrals to proficient HCPs with these skills. 
An efficient, expedited referral system will help unskilled HCPs to gain confidence in 
recommending IUDs, by assuring that their patient can easily access this service. Furthermore, it 
can instill trust among patients receiving this service.   
Understanding indications and contraindications. It is paramount that all providers 
offering contraception have a strong knowledge of the indications and contraindications for all 
forms of contraception. Specifically, providers need improved education of WHO MEC, as this 
has been identified as an area of misunderstanding among many HCPs (Black et al., 2012). Of 
importance are young nulliparous women, as they are often informed that nulliparity is a 
contraindication to receive an IUD (Berlan, Pritt, & Norris, 2016; da Silva-Filho et al., 2016; 
Pritt, Norris & Berlan, 2016; Rubin, Coy, Yu, & Muncie, 2016). This misinformation persists 
despite nulliparous women under 20 being MEC category 2 for all IUDs: “the advantages of 
using the method generally outweigh the theoretical or proven risks” (WHO, 2015, p.5). By 
improving contraception education through enhanced understanding of indications and 
contraindications for all contraceptive methods, the rates of reliable contraception may increase, 
particularly for IUDs (Navarria, Julen, Narring, & Yaron, 2015).  
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Improving training opportunities. There appear to be recent ongoing curriculum 
changes directed towards improving IUD training and knowledge among HCPs (Black et al., 
2013; Kruithof, 2017). Though this is promising, improved education and training is important, 
especially for providers with less recent training. Additionally, continuing medical education to 
maintain this proficiency is essential (Luchowski et al., 2014). In a skill-based training initiative 
Lewis, Darney and Thiel de Bocanegra (2013) held several training sessions for several months. 
They found that this initiative improved the rates of correctly identified IUD candidates, 
especially among nulliparous and adolescent women. The effects of this study are especially 
strong among smaller, low volume clinics. It is, therefore, important that we encourage 
continuing medical education directed specifically at improving contraception knowledge among 
smaller, low-volume clinics.  
Recommendations for the IUD user 
I have identified that a significant barrier to IUD use is attributed to a general lack of 
public knowledge about IUDs (Hall et al., 2016; Hauck & Costescu, 2015; Okpo et al., 2014; 
Rubin & Winrob, 2010). The focus of this section of recommendations will be on improving 
public knowledge by reducing misinformation and raising awareness about the IUD. The 
CRNBC Nurse Practitioner competencies state that NPs “provide information that is current, 
relevant and evidence informed” for each client’s unique circumstance (CRNBC, 2015, p.11). 
This competency is set forth by our College, and will be at the heart of these recommendations.  
It is important to pause for a moment and make the distinction between providing 
education, and coercion. I want to be unequivocal in stating that the goal is not to coerce women 
into choosing an IUD. Instead, the focus is on improving the accuracy and accessibility of 
contraceptive knowledge so that fully informed, patient-centered choices are made. This 
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distinction is important to make, as the goal is to assure that comprehensive contraceptive 
information is available to all women so that they can make informed decisions centered on their 
values and priorities. Some women, for example, value having personal control over when they 
can personally initiate or terminate their contraception (Gomez et al., 2015). For these women, 
IUDs may not be their contraceptive method of choice; instead, they may want to choose a more 
easily controllable method such as oral contraception. For other women who prefer reliability, 
efficacy, and simplicity, and who do not mind handing over the physical process of contraceptive 
initiation and termination, IUDs may be a good option. Regardless of her values, beliefs, or 
priorities, it is important that each woman has the necessary information about all contraceptive 
methods so she can make a fully informed decision (Hall et al., 2016).  
Many women have already decided on a contraceptive method before they have met with 
their prescriber (Okpo et al., 2014). Some women may look to their friends, family, TV, or they 
go online for their information (Gomez et al., 2015). The result is that their information may be 
inaccurate or incomplete (Hauck & Costescu, 2015; Rubin & Winrob, 2010). For example, a 
woman with a friend who had a negative experience from an IUD may be reluctant to receive 
one. It is important that HCPs validate these concerns despite being anecdotal. Taking these 
personal experiences into consideration is a crucial step towards building trust with the provider 
and the healthcare system.  
A public education initiative is another method that could be implemented to help 
improve public knowledge and raise awareness of IUDs. The purpose is to extend education 
beyond what is provided by the HCPs in primary care, and into the hands of policy makers 
within primary health care. Changes in primary health care, as opposed to primary care, involve 
changes on a large-scale systems-level, impacting entire populations rather than individuals. 
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Primary health care policy changes could improve awareness through education of all 
contraceptive methods, including IUDs, increasing awareness of their efficacy, safety, 
reversibility, and mechanism of action. These changes could also help to dispel myths about 
these contraceptive methods. It has been shown that by improving public knowledge of all 
methods of contraception, the rates of reliable contraception, especially IUDs will increase 
(Secura et al., 2010). Nobiling and Drolet (2012) concluded that “health educators can use social 
marketing principles to create public awareness of the safety and efficacy of IUDs” (p. 22). An 
example of a social marketing tool could use a medium such as social media. The ubiquitous 
medium of social media could be utilized in an innovative marketing tool to help improve 
contraceptive knowledge among young women.  
Recommendations for Systems-Level Changes 
Nurse practitioners have the responsibility to effect change at the systems-level of 
healthcare. This responsibility means that their role extends beyond direct patient care, and 
includes identifying unmet health needs, making changes in health systems, and ongoing re-
evaluation of these changes (CNA, 2016, p.2). It is clear that there is an unmet need to improve 
contraception in Canada. Specifically, IUDs are an area where improvement should occur. This 
final section of recommendations focuses on systems-level changes that Nurse Practitioners can 
make to improve the accessibility of IUDs for all Canadian women. 
Reducing the barrier of cost. A major system-wide barrier to IUD use is the upfront and 
out of pocket cost of each device. Even though this expense is incurred every 3-10 years, and the 
long-term cost is less than most other contraceptive options, the upfront cost of IUDs is 
identified as a prohibitive barrier, especially among teens (Eisenberg, McNicholas & Peipert, 
2013). The simplest solution to this barrier begins with an improved understanding of the actual 
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price, as some women may have an inflated perception of cost. Some women may be either 
unaware of the actual price, or they may not have made a direct comparison between each 
method. For example, the Mirena, which costs approximately $360 (Island Sexual Health, 2014) 
can be used for up to 5 years, equating to as little as $6 per month.  
Another pragmatic solution to reducing the perception of excessive cost is by improving 
awareness of extended medical insurance coverage. For example, Studentcare, which provides 
extended medical benefits for 750 000 Canadian students, will pay for 80% of prescription 
medication, including IUDs (Student Care, 2017). By improving awareness of this coverage, a 
student may be more inclined to choose an IUD. Similarly, those covered under the Non-Insured 
Health Benefits (NIHB) program have 100% coverage for many of their prescription medications 
including copper and hormone-based IUDs (Government of Canada, 2016). Improving 
awareness of one’s own coverage can enhance IUD uptake among Canadian students, Canadians 
covered under NIHB, and those covered with extended medical benefits. It is imperative that 
HCPs understand the nuances of these costs, so they can make recommendations that that are 
congruent with their patients’ financial resources.  
A unique initiative similar to BCs QuitNow.ca campaign, which provides publically 
funded smoking cessation medication for any British Columbian, could offer publically funded 
contraception for young women. The rationale for the QuitNow program is that by reducing the 
number of smokers in BC, we can improve the health of our Province’s population and decrease 
the burden on our healthcare system (Bottorff et al., 2016). A publically funded contraception 
program would follow the same logic. It has been shown that publically funded contraception 
programs improve IUD rates and reduce unplanned pregnancies (Cook & Fleming, 2010; Secura 
et al., 2010; Udeh et al., 2009). It would be crucial for this initiative to not focus on only IUDs; 
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instead, it should provide publically funded contraception of all methods. Reassuringly, it has 
been shown that by eliminating the personal cost associated contraception, women have a higher 
tendency to choose IUDs (Secura et al., 2010). An initiative such as this, involving changes in 
the delivery of pharmaceuticals must include a strong collaborative partnership with pharmacists. 
Pharmacists are an excellent resource, with a strong understanding of medicine, and their 
collaboration could act as low barrier access point for women to obtain contraception. 
Reducing the barrier of accessibility. Changing how contraception is dispensed can 
also effect change. For example, reducing barriers associated with multiple visits to the clinic 
and the pharmacy can improve IUD use (Luchowski et al., 2014). We could achieve this change 
by encouraging clinics to stock IUDs, eliminating the barrier of having to access a pharmacy and 
then return to the clinic for insertion. Since multiple visits are associated with low IUD use 
(Bergin et al. 2012; Stanek et al., 2009), reducing them may further reduce barriers to their use. 
Assuring that HCPs possess the requisite knowledge and training so that they are not restricting 
access to IUDs by introducing needless cumbersome investigations would most certainly reduce 
barriers to their use.  
Reducing the barrier of product labeling. As I have discussed, there are 
inconsistencies in product labeling among various IUD devices (Bayer, 2014a; Bayer, 2014b). 
Accurate and consistent product labeling is necessary for public and provider information, as it 
assures that options are properly understood. As agents of change, NPs can take a political and 
public stance to advocate for accurate product labeling, so the Jaydess and Mirena IUD 
monographs contain consistent and evidence-based information. Consistent labeling is especially 
important in Canada, as we move towards introducing a third LNG-IUD, the Kyleena 
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(Government of Canada, 2017). It is imperative that product labeling is consistent and accurate 
among all devices. 
Changes in three broad areas can affect change by improving access to IUDs in Canada. 
One main area of focus improves IUD knowledge and skills among HCPs. Additionally, 
improving public understanding about IUDs and effecting system-level changes will also ensure 
that these devices remain accessible. 
Recommendations for future research.  
This recommendation section has been based on the evidence retrieved from the literature 
using the methods previously described. Undoubtedly some perspectives have been missed. This 
may be due to gaps in the literature, or it may be from imperfect search methods. In either case, 
several important perspectives were not identified in the literature, and therefore not yet 
discussed. This brief section is devoted to presenting these perspectives as areas for future 
research. 
First, it is important that we address the fact that contraception is inherently gendered. As 
discussed, the only contraceptive method directly used by men are male condoms and 
vasectomies. Furthermore, the major consequence of unreliable contraception: unplanned 
pregnancies, are mostly borne by women. Since no literature discussed how this gender bias 
could act as a barrier to contraception, future research could help fill this gap.    
Secondly, we must consider that women of different ages face different obstacles when 
obtaining contraception. For example, a young teenaged woman may face unique challenges 
compared to an older woman when seeking contraception. It is paramount that we consider this 
young subpopulation, as they are highly vulnerable to the burden of unplanned pregnancies. 
Future research that focuses on teenaged women seeking contraception for the first time would 
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help identify unique barriers that they face. In considering young women, we must also ask the 
question: when should contraception education first occur? Is it the role of the school system, the 
healthcare system; or should it fall on the shoulder of parents to provide this education? Again, it 
would be valuable to see these questions answered by future research. Since the omnipresence of 
social media is ever-expanding, it is likely that social media can contribute to contraception 
education. Research devoted to how social media can be best used to provide this education 
would also be a valuable contribution to future studies.   
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Chapter 5: Conclusion 
More than 180 000 unplanned pregnancies occur in Canada annually (Black et al., 2015) 
most of which occur among youth, First Nations, and women of low socio economic class 
(Aptekman et al., 2014). The burden of unplanned pregnancies is high, resulting in greater 
maternal and fetal complications, and significant financial strain on the healthcare system (Black 
et al., 2015). To reduce unplanned pregnancies, women require reliable contraception. 
There are many forms of contraception available in Canada each with their pros and cons. 
Most Canadian women depend on either oral contraception or male condoms (United Nations, 
2011), both of which are highly susceptible to typical-use failure (Sundaram et al., 2017). IUDs, 
on the other hand, are highly effective, safe and reversible; and they are less susceptible to 
typical-use failure (Polis et al., 2016). Unfortunately, few Canadian women choose this method, 
especially when compared to other countries (United Nations, 2011), this is despite 
recommendations by the SOGC that IUDs should be offered as a first-line method of 
contraception (Black et al., 2016).  
The purpose of this literature review was to identify potential barriers that Canadian 
women face obtaining IUDs, and to make recommendations towards eliminating these barriers. 
These recommendations are directed towards Family Nurse Practitioners. They were chosen as 
the focus of these recommendations as they are positioned clinically, politically, and 
professionally to initiate changes at a clinical, administrative, policy and political level. Despite 
the focus on FNPs, any healthcare provider, administration, policy maker, or politician would 
benefit from this discussion as they all play a crucial role in accessible health care to all 
Canadians. 
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 Peer reviewed data was collected from a thorough literature review of medical, nursing, 
social science and financial databases. Additionally, discussions from the online blog Reddit, and 
face to face discussions with HCPs provided informal, yet valuable data on this topic.  
The reasons for the underutilization of IUDs in Canada are broad and multifaceted. A 
collection of barriers that could be contributing to their underutilization was identified. 
Subsequently, I made a series of recommendations to help eliminate each of these barriers. The 
barriers to IUDs and the recommendations for each are in Table 7. 
Table 7 
 
A Summary of the Findings and Recommendations 
Barriers to IUD use Recommendations for improvement 
Poor HCP knowledge about IUDs Improved awareness through provider education. 
Difficult IUD insertions Improved skill through provider training. 
Excessive perception of risk Improved knowledge of WHO MEC through 
education 
HCPs concern of pain with IUD 
insertion 
Improved pain management techniques, and a 
better understanding of the pain in can cause 
HCP misunderstanding of the MOA Improved training 
Lack of public awareness about IUDS Public health education campaigns 
Lack of public understanding of their 
MOA, safety, efficacy, and reversibility 
Public education and awareness 
Personal values that do not align with 
those which are conducive with the 
IUD 
Not a barrier that needs to be overcome, rather a 
consideration that needs to be made with informed 
choice. 
Personal cost Improved awareness of actual long-term cost. 
Improved awareness of ones extended medical 
coverage. 
Public initiatives that could cover contraception – 
would be cost effective in the long-run. 
Confusing labeling of the IUDs Advocate that the manufacturers have consistent 
labeling among devices 
Multiple office visits Encourage clinics to stock IUDs to facilitate same-
day insertions. 
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It is my hope that by following these recommendations we can limit the barriers 
attributed to IUDs, improve the accessibility of reliable contraception for Canadian women, and 
preventing unplanned pregnancies.  
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Appendix 1 
Contraindications for the Mirena IUD, adopted from Bayers monograph (Bayer, 2014) 
 
• known or suspected pregnancy 
• current or recurrent pelvic inflammatory disease 
• lower genital tract infection 
• postpartum endometritis 
• undiagnosed abnormal uterine bleeding  
• uterine anomalies including fibroids if they distort the uterine cavity 
• uterine or cervical malignancy 
• known or suspected progestin-dependent neoplasia, including breast cancer 
• cervicitis 
• cervical dysplasia 
• active liver disease or dysfunction  
• actual benign or malignant liver tumors 
• septic abortion within the previous three months 
• hypersensitivity to levonorgestrel or any of the other ingredients in the formulation or 
component of the container components of MIRENA 
• bacterial endocarditis 
• established immunodeficiency 
• acute malignancies affecting blood or leukemias 
• recent trophoblastic disease while hCG levels are elevated 
 
Contraindications for the Jaydess IUD, adopted from Bayers monograph (Bayer, 2014) 
• Known or suspected pregnancy 
• current or recurrent pelvic inflammatory disease or conditions associated with increased 
risk for pelvic infections 
• postpartum endometritis or septic abortion during the previous three months  
• abnormal vaginal bleeding of unknown etiology 
• uterine anomalies including fibroids if they distort the uterine cavity 
• uterine or cervical malignancy 
• known or suspected progestogen-dependent neoplasia, including breast cancer 
• cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections  
• until infection is controlled 
• cervical dysplasia 
• active liver disease or dysfunction 
• actual benign or malignant liver tumor  
• hypersensitivity to levonorgestrel or any of the other ingredients in the formulation or  
• component of the container components of JAYDESS 
• a previously inserted intrauterine device (IUD) that has not been removed 
• recent trophoblastic disease while hCG levels are elevated 
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• bacterial endocarditis 
 
Contraindications for the Kyleena IUD, adopted from Bayers monograph (Bayer, 2016) 
• known or suspected pregnancy 
• current or recurrent pelvic inflammatory disease or conditions associated with increased 
risk for pelvic infections 
• postpartum endometritis or septic abortion during the previous three months 
• abnormal uterine bleeding of unknown etiology 
• congenital or acquired uterine anomaly, including fibroids, that distort the uterine cavity 
• uterine or cervical malignancy 
• known or suspected progestogen-dependent neoplasia, including breast cancer 
• cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections 
until infection is controlled 
• cervical dysplasia  
• active liver disease or dysfunction  
• actual benign or malignant liver tumours  
• hypersensitivity to levonorgestrel or any of the other ingredients in the formulation or 
component of the container components of a previously inserted intrauterine 
contraceptive (IUC) that has not been removed 
• recent trophoblastic disease while hCG levels are elevated 
• bacterial endocarditis 
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Appendix 2 
A Sample of IUD Related comments online from Reddit 
Topic Comment Author 
Cost “I would like to try an IUD, if I ever have health 
insurance” 
you_stupid_people 
Pain for man 
during 
intercourse 
“My girlfriend has one and it does hurt me, quite a 
lot. She's had it checked and has been told 
everything is normal” 
Raphael Rodriguez 
 
Insertion pain “I didn't have any pain killer and I just got it pushed 
in, I am 16. No kids, and it didnt hurt. I was on my 
feet within a minute” 
Katie_Konnort 
 “Insertion is screaming agony. Anyone who tells 
you otherwise is lying” 
No_name 
 “I got Mirena the first time 5 years ago. It was agony 
(I literally cried and screamed, and probably 
sounded like someone in labor). With that said, I'll 
be soon setting up the appointment for my 
replacement. Even knowing how intense the pain 
was, the five years I had of no periods and no pain (I 
have endometriosis) and the happy side effect of a 
better mood... you bet I'll be getting it again.” 
aldona 
 “It didn't help that I read all of the horror stories 
online about the pain before I went in. Probably only 
made it worse” 
KaylaLittle 
 In response to someone asking if an IUD can be 
removed after 4 weeks of moderate cramping: “It's 
your choice if you want it removed but honestly, 
you're not giving it time to adjust to your body.” 
ChocoboDeath 
Accurate info In response to concerns about IUD perforation 
“perforation isn't really as scary as it sounds. It is 
super rare and you heal insanely quickly” 
Silly_Willy 
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Appendix 3 
PRISMA checklist adopted from Moher, Liberati, Tetzlaff and Altman (2009) 
Title  Identify the report as a systematic review, meta-analysis, or both.  
ABSTRACT: 
Structured 
summary  
Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings. 
INTRODUCTION  
Rationale  Describe the rationale for the review in the context of what is already 
known.  
Objectives  Provide an explicit statement of questions being addressed with reference 
to participants, interventions, comparisons, outcomes, and study design 
(PICOS).  
METHODS  
Protocol and 
registration  
Indicate if a review protocol exists, if and where it can be accessed (e.g., 
Web address), and, if available, provide registration information including 
registration number.  
Eligibility criteria  Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used 
as criteria for eligibility, giving rationale.  
Information 
sources  
Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched.  
Search  Present full electronic search strategy for at least one database, including 
any limits used, such that it could be repeated.  
Study selection  State the process for selecting studies (i.e., screening, eligibility, included 
in systematic review, and, if applicable, included in the meta-analysis).  
Data collection 
process  
Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
Data items  List and define all variables for which data were sought (e.g., PICOS, 
funding sources) and any assumptions and simplifications made.  
Risk of bias in 
individual studies  
Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis.  
Summary 
measures  
State the principal summary measures (e.g., risk ratio, difference in 
means).  
Synthesis of results  Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g., I2) for each meta-analysis.  
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Appendix 4 
Critical Appraisal Skills Program (CASP) Randomized Controlled Trials Checklist. Adapted 
from Oxman et al., (1994) and Critical Appraisal Skills Programme (2017a). 
Section Question to ask 
A: Are the 
results of the 
trial valid?  
 
 
1. Did the trial address a clearly focused issue?  
2. Was the assignment of patients to treatments randomized? 
Is it work continuing: Yes or No? 
3. Were all the patients who entered the trial properly accounted for at its 
conclusion?  
4. Were patients, health workers and study personnel ‘blind’ to treatment?  
5. Were the groups similar at the start of the trial? 
6. Aside from the experimental intervention, were the groups treated equally? 
B: What are the 
results? 
7. How large was the treatment effect? 
8. How precise was the estimate of the treatment effect? 
C: Will the 
results help 
locally? 
 
9. Can the results be applied in your context? (or to the local population?) 
10. Were all clinically important outcomes considered? 
11. Are the benefits worth the harms and costs? 
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Appendix 5 
Critical Appraisal Skills Program (CASP) Cohort Study Checklist. Adapted from Oxman et al., 
(1994) and Critical Appraisal Skills Programme (2017b). 
Section Question to ask 
A: Are the 
results of the 
trial valid?  
 
 
1. Did the trial address a clearly focused issue?  
2. Was the cohort recruited in an acceptable way? 
Is it worth continuing: Yes or No? 
3. Was the exposure accurately measured to minimize bias? 
4. Was the outcome accurately measured to minimize bias? 
5. a) have the authors identified all the important confounding factors? 
b) have they taken account of the confounding factors in the design and/or 
analysis? 
6. a) Was the follow up of subjects complete enough? 
b) was the follow up of subjects long enough? 
B: What are the 
results? 
 
7. Wat are the results of this study? 
8. How precise are the results?  
9. Are the results believable? 
C: Will the 
results help 
locally? 
10. Can the results be applied to the local population? 
11. Do the results of this study fit with the over available evidence.  
What are the implications of this study for practice? 
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Appendix 6 
Critical Appraisal Skills Program (CASP) Qualitative Research Checklist. Adapted from Oxman 
et al., (1994) and Critical Appraisal Skills Programme (2017c). 
Section Question to ask 
A: Are the 
results of the 
trial valid?  
 
 
1. Was there a clear statement aiming the research? 
2. Is a quanlitative method appropriate? 
Is it worth continuing: Yes or No? 
3. Was the design appropriate to address the goal? 
4. Was the recruitment strategy appropriate? 
5. Was the data collection in a way that addressed the research issue? 
6. Has the relationship between the researcher and the participants been adequately 
considered? 
B: What are the 
results? 
7. Have ethical issues been taken into consideration?  
8. Was the data analysis sufficiently rigorous?  
9. Is there a clear statement of findings? 
10. How valuable is the research? 
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Appendix 7 
Critical Appraisal Skills Program (CASP) Case Control Study Checklist. Adapted from Oxman 
et al., (1994) and (Critical Appraisal Skills Programme, 2017d) 
Section Question to ask 
A: Are the 
results of the 
trial valid?  
 
 
1. Did the study address a clearly focused issue? 
2. Did the authors use an appropriate method to answer their question? 
Is it worth continuing: Yes or No? 
3. Was the case recruited in an acceptable way? 
4. Were the controls selected in an acceptable way? 
5. Was the exposure accurately measured to minimize bias? 
6. a) What confounding factors have the authors accounted for? 
6. b) Have the authors taken account of the potential confounding factors in the 
design and/or in their analysis? 
B: What are the 
results? 
7. What are the results of this study?  
8. How precise are the results?  
9. Do you believe the results 
C: Will the 
results help 
locally? 
10. Can the results be applied to the local population? 
11. Do the results of this study fit with other available evidence? 
 
 
 
 
 
 
